Skip to content

Clinical observation of transcutaneous electrical nerve stimulation in the treatment of postherpetic neuralgia

Clinical observation of transcutaneous electrical nerve stimulation in the treatment of postherpetic neuralgia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075833
Enrollment
Unknown
Registered
2023-09-17
Start date
2023-09-17
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Paravertebral nerve block group:All subjects were treated with nerve root block on the basis of routine drug treatment. All PHN patients were treated with oral drugs before seeing a doctor, and the pa
Percutaneous electrical stimulation group combined with paravertebral block group:Transcutaneous electrical nerve stimulation was performed on the basis of paravertebral nerve block. According to the
Spinal cord electrical stimulation combined with paraspinal nerve block group:On the basis of routine drugs and paravertebral nerve block treatment, all participants were routinely treated with spinal
Percutaneous electrical nerve stimulation, spinal cord electrical stimulation combined with paravertebral nerve block group:All participants were treated with routine transcutaneous electrical nerve s

Sponsors

The Fourth Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Meet the PHN diagnostic criteria: there is a history of acute herpes zoster, the pain lasts for more than one month, and there is severe paroxysmal pain, and the pain properties are like burning, acupuncture, grasping, knife cutting and electric shock. (2) Oral analgesics include pregabalin, tramadol hydrochloride, etc., and those with poor conservative treatment such as physical therapy. (3) visual analogue scale,VAS) score =6. (4) Voluntary participation in this study, and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Complicated with serious medical diseases, such as cardiopulmonary diseases or abnormal liver and kidney functions; (2) Severe coagulation dysfunction; (3) Infection, ulceration and tumor at the puncture site; (4) Suffering from severe mental illness, with cognitive impairment. (5) Refusing to participate in this study.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;

Secondary

MeasureTime frame
Pittsburgh sleep quality index(PSQI);self-rating anxiety scale, SAS;

Countries

China

Contacts

Public ContactHuacheng Zhou

The Fourth Affiliated Hospital of Harbin Medical University

zhouhuacheng@163.com+86 139 3618 4872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026